Pradžia › Kastračiai atspari prostatos vėžys › Kalifornija
Kastračiai atspari prostatos vėžys klinikiniai tyrimai Kalifornija
11 tyrimai dėl Kastračiai atspari prostatos vėžys ieško dalyvių vietose Kalifornija.
Miestai Kalifornija
Oficialus tyrimo tekstas (anglų kalba)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- MemorialCare Orange Coast Medical Center, Fountain Valley
- University Of California San Diego, La Jolla
- Cancer and Blood Specialty Clinic, Los Alamitos
- ir dar 6
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- University of California at San Diego, La Jolla
- Cedars Sinai Medical Center, Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles
- ir dar 1
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-25 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START Los Angeles, Los Angeles
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-24 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UCLA Hematology & Oncology ( Site 0003), Los Angeles
- University of California-Irvine Medical Center ( Site 0016), Orange
- UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- UCSD Moores Cancer Center ( Site 0039), La Jolla
- UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- UCI Health Chao Family Comprehensive Cancer Center, Orange
- Investigational Site Number: 403, Palo Alto
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-09-10 · NCT05997615Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
- ir dar 2
Renkami dalyviai1 fazė
Amžius nuo 18 iki 100 · Vyrams · Atnaujinta 2026-08-13 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-11 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Stanford Cancer Center, Palo Alto
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-08-10 · NCT0606784164Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Stanford Cancer Institute, Stanford
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2026-05-06 · NCT0486860418F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- VA Greater Los Angeles Healthcare System, Los Angeles
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Vyrams · Atnaujinta 2024-11-27 · NCT06706921Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.